PBAC's latest decision on Fingolimod, ofatumumab, siponimod: Recommended with restriction (2024). Considered for Amendment to PBS listings to allow nurse practitioners to initiate and continue treatment of fingolimod, ofatumumab, and siponimod in consultation with a specialist physician for the treatment of multiple sclerosis.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Patients with multiple sclerosis (relapsing-remitting MS for fingolimod and ofatumumab; secondary progressive MS for siponimod) suitable for treatment by nurse practitioners in consultation with a specialist physician.
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
This is a Category 4 submission requesting a prescriber change amendment with no new clinical or economic evaluation; no ICER calculated.